Defeat DIPG Executive Director Jenny Mosier Speaks at FDA Public Hearing Regarding ONC201
AuburnExaminer: Defeat DIPG Executive Director Jenny Mosier Speaks at FDA Public Hearing Regarding ONC201. The full article can be found here.
-
Our Team
Our drug development team has a proven record of translating promising discoveries into therapeutics that profoundly change medical practice.Learn more -
Our Science
Our approach uses a new class of compounds called imipridones to selectively target G protein-coupled receptors (GPCRs) that control critical signaling pathways in cancer.Learn more -
Alliances
Rutgers Cancer Institute of N.J., MD Anderson Cancer Center and Mass. General Hospital/Dana Farber Cancer Institute are conducting ONC201 clinical trials.Learn more
In The News
-
JUL 01 2019
-
-
MAY 29 2019
BioSpace: ASCO 2019 Preview: Presentations to Keep An Eye On
Oncoceutics, Inc. – Philadelphia-based Oncoceutics, Inc. will showcase data from its ongoing trial assessing ONC201 in adult recurrent H3 K27M-mutant glioma. The oral abstract session presentation, entitled “Single agent ONC201 in adult recurrent H3 K27M-mutant glioma” will describe the clinical experience of ONC201, in adults with recurrent H3 K27M-mutant glioma. ONC201 is an orally active
-
Business Development
© Copyright 2016 Oncoceutics, Inc. All Rights Reserved.